±¤µ¿ ¾ÏÇмú»ó¿¡ Ãֱͼ±-ÀÌÀº°æ-±èÁ¤ÇÑ ¼ö»ó

¾Ï ºÐ¾ß ¿¬±¸ÀÚ Áß ±âÃÊ, ÀÓ»ó, ´Ù¼ö ³í¹® ºÐ¾ßº° ¼ö»óÀÚ ¼±Á¤
´º½ºÀÏÀÚ: 2018³â06¿ù22ÀÏ 15½Ã38ºÐ

±¹¸³¾Ï¼¾ÅÍ ¾Ï°ü¸®Çаú Ãֱͼ± ±³¼ö, °©»ó¼±¾Ï¼¾ÅÍ ÀÌÀº°æ ±³¼ö, ÇѸ²ÀÇ´ë Ç÷¾×Á¾¾ç³»°ú ±èÁ¤ÇÑ ±³¼ö

[º¸°ÇŸÀÓÁî] ±¤µ¿Á¦¾à(´ëÇ¥ÀÌ»ç ÃÖ¼º¿ø)Àº ±¹¸³¾Ï¼¾ÅÍ ¾Ï°ü¸®Çаú Ãֱͼ± ±³¼ö¿Í °©»ó¼±¾Ï¼¾ÅÍ ÀÌÀº°æ ±³¼ö, ÇѸ²ÀÇ´ë Ç÷¾×Á¾¾ç³»°ú ±èÁ¤ÇÑ ±³¼ö µî¿¡°Ô ‘Á¦7ȸ ±¤µ¿ ¾ÏÇмú»ó’À» ¼ö¿©Çß´Ù°í ¹àÇû´Ù.

Ãֱͼ± ±³¼ö

ÀÌÀº°æ ±³¼ö

±èÁ¤ÇÑ ±³¼ö

±¤µ¿ ¾ÏÇмú»óÀº ¾Ï ºÐ¾ß¿¡¼­ Ź¿ùÇÑ ¿¬±¸ ½ÇÀûÀ» ¹ÙÅÁÀ¸·Î SCI±Þ Àú³Î¿¡ ³í¹®À» ¹ßÇ¥ÇØ ±¹³» ¾Ï¿¬±¸ ¹ßÀü¿¡ ±â¿©ÇÑ ¿¬±¸ÀÚµé Áß ±âÃÊÀÇÇаú ÀÓ»óÀÇÇÐ, ´Ù¼ö ³í¹® ¹ßÇ¥ÀÇ ¼¼ ºÎ¹®À¸·Î ³ª´² ¼ö¿©µÈ´Ù.

2017³â ÇÑ ÇØ µ¿¾È À¯¼öÀÇ SCI±Þ ÇÐȸÁö¿¡ ¹ßÇ¥µÈ ±âÃÊÀÇÇÐ ³í¹®À» ´ë»óÀ¸·Î ¼±Á¤ÇÑ ±âÃÊÀÇÇÐ ºÎ¹®Àº Gastroenterology(2017 May, IF 18.392)¿¡ ¹ßÇ¥µÈ ‘Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality’¸¦ °øµ¿ ÁýÇÊÇÑ ±¹¸³¾Ï¼¾ÅÍ ¾Ï°ü¸®Çаú Ãֱͼ± ±³¼ö¿Í ¿¬¼¼ÀÇ´ë ¿¹¹æÀÇÇаú ¹ÚÀºÃ¶ ±³¼ö¿¡°Ô µ¹¾Æ°¬´Ù. ±¹¸³¾Ï¼¾ÅÍ °©»ó¼±¾Ï¼¾ÅÍ ÀÌÀº°æ ±³¼ö¿Í ¼­¿ïÀÇ´ë »ýÈ­Çаú ±èÁ¾ÀÏ ±³¼ö, ³»ºÐºñ³»°ú ¹Ú¿µÁÖ ±³¼ö´Â Nat Commun.(2017 Jul, IF 12.124)¿¡ °ÔÀçµÈ ‘Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer’ ³í¹®À» ¹ßÇ¥ÇØ ÀÓ»óÀÇÇÐ ºÎ¹® ¼ö»óÀÇ ¿µ¿¹¸¦ ¾È¾Ò´Ù.

ÇѸ²ÀÇ´ë Ç÷¾×Á¾¾ç³»°ú ±èÁ¤ÇÑ ±³¼ö´Â Oncotarget(2017 Aug, IF 5.168)¿¡ ½Ç¸° ‘The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials’ µî ¿©·¯ ÆíÀÇ ³í¹®À» ¹ßÇ¥ÇÑ °ø·Î·Î ´Ù¼ö ³í¹® ¹ßÇ¥ ºÎ¹®À» ¼ö»óÇß´Ù.

±¤µ¿Á¦¾à °ü°èÀÚ´Â “±¹³» ÀÇ·áÁøÀÇ ¾Ï ¿¬±¸°¡ ²ÙÁØÈ÷ ¹ßÀüÇØ ±¹¹Î °Ç°­ÀÌ Çâ»óµÉ ¼ö ÀÖµµ·Ï Áö¼ÓÀûÀ¸·Î Áö¿øÇÒ °èȹ”À̶ó°í ¸»Çß´Ù.

Á¦7ȸ ±¤µ¿ ¾ÏÇмú»ó ½Ã»ó½ÄÀº 6¿ù 22ÀÏ ¼­¿ï ¼Ò°øµ¿ ·Ôµ¥È£ÅÚ¿¡¼­ °³ÃÖµÈ ‘Á¦44Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦4Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º’ Çà»ç Áß ´ëÇѾÏÇÐȸ Çмú´ëȸ Á¤±âÃÑȸ¿¡¼­ ÁøÇàµÆÀ¸¸ç ¼ö»óÀڵ鿡°Ô´Â °¢°¢ 500¸¸¿øÀÇ »ó±Ý°ú »óÀåÀ» ¼ö¿©Çß´Ù.


ÀÌ ´º½ºÅ¬¸®ÇÎÀº BKT´º½º{www.bktimes.net}¿¡¼­ ¹ßÃéµÈ ³»¿ëÀÔ´Ï´Ù.